205 results on '"Larrauri, Amparo"'
Search Results
2. Comparative severity of COVID-19 cases caused by Alpha, Delta or Omicron SARS-CoV-2 variants and its association with vaccination
- Author
-
Varea-Jiménez, Elena, Aznar Cano, Esteban, Vega-Piris, Lorena, Martínez Sánchez, Elena Vanessa, Mazagatos, Clara, García San Miguel Rodríguez-Alarcón, Lucía, Casas, Inmaculada, Sierra Moros, María José, Iglesias-Caballero, Maria, Vazquez-Morón, Sonia, Larrauri, Amparo, and Monge, Susana
- Published
- 2024
- Full Text
- View/download PDF
3. Effectiveness of mRNA vaccine boosters against infection with the SARS-CoV-2 omicron (B.1.1.529) variant in Spain: a nationwide cohort study
- Author
-
Moreno, David, Méndez Díaz, Manuel, Huerta González, Ismael, Galmés Truyols, Antònia, Barreno Estévez, Ana, García Velasco, Valvanuz, Rodríguez Recio, Mª Jesús, Sacristán, José, Martínez Marcos, Montserrat, Pastor Villalba, Eliseo, Macías Ortiz, María José, García Vallejo, Ana, Sánchez Gómez, Amaya, García Pina, Rocío, Barricarte Gurea, Aurelio, Sancho Martínez, Rosa, Ochoa, Eva María, Vázquez Cantero, Mauricio, Gómez Anés, Atanasio, Pareja Megía, María Jesús, Castán, Yolanda, Fonseca Álvarez, Manuel Roberto, Salvà Fiol, Antonia, Sánchez Janáriz, Hilda, López Arce, Luz, Cisneros Martín, María Ángeles, Gibernau, Frederic Jose, Fernandez Buey, Cesar, Villatoro Bongiorno, Katja, Rubio García, Francisco Javier, Santos Guerra, Fernando, Astray Mochales, Jenaro, Francisco Verdu, Francisco Javier, García Romero, Isabel, Oriza Bernal, Rosa, Gómez Pérez, Tomás, Hijano Villegas, Salomé, Román Soto, Sergio, Gómez-Barroso, Diana, Lapeña, María Fé, Yagüe Galaup, Virgilio, Alfaro Latorre, Mercedes, Aguilera Guzmán, Marta, Crespo Sánchez-Eznarriaga, Belén, Neira León, Montserrat, Cívicos Villa, Noemí, Monge, Susana, Rojas-Benedicto, Ayelén, Olmedo, Carmen, Mazagatos, Clara, José Sierra, María, Limia, Aurora, Martín-Merino, Elisa, Larrauri, Amparo, and Hernán, Miguel A
- Published
- 2022
- Full Text
- View/download PDF
4. Regional excess mortality during the 2020 COVID-19 pandemic in five European countries
- Author
-
Konstantinoudis, Garyfallos, Cameletti, Michela, Gómez-Rubio, Virgilio, Gómez, Inmaculada León, Pirani, Monica, Baio, Gianluca, Larrauri, Amparo, Riou, Julien, Egger, Matthias, Vineis, Paolo, and Blangiardo, Marta
- Published
- 2022
- Full Text
- View/download PDF
5. Perimeter confinements of basic health zones and COVID-19 incidence in Madrid, Spain
- Author
-
García-García David, Herranz-Hernandez Rafael, Rojas-Benedicto Ayelén, León-Gómez Inmaculada, Larrauri Amparo, Peñuelas Marina, Guerrero-Vadillo María, Ramis Rebeca, and Gómez-Barroso Diana
- Subjects
Covid-19 ,Madrid ,Spain ,Perimeter closures ,Public aspects of medicine ,RA1-1270 - Abstract
Abstract Background A unique policy of perimeter closures of Basic Health Zones (small administrative health units) was implemented in the Autonomous Community of Madrid from September 21st 2020 to May 23rd 2021 to face the COVID-19 pandemic. Aim To assess the impact of local perimeter confinements on the 14-days cumulative incidence of SARS-CoV-2 during the second wave of the pandemic in Madrid, Spain. Methods We compare the errors in estimation of two families of mathematical models: ones that include the perimeter closures as explanatory covariables and ones that do not, in search of a significant improvement in estimation of one family over the other. We incorporate leave-one-out cross-validation, and at each step of this process we select the best model in AIC score from a family of 15 differently tuned ones. Results The two families of models provided very similar estimations, for a 1- to 3-weeks delay in observed cumulative incidence, and also when restricting the analysis to only those Basic Health Zones that were subject to at least one closure during the time under study. In all cases the correlation between the errors yielded by both families of models was higher than 0.98 (±10− 3 95% CI), and the average difference of estimated 14-days cumulative incidence was smaller than 1.49 (±0.33 95% CI). Conclusion Our analysis suggests that the perimeter closures by Basic Health Zone did not have a significant effect on the epidemic curve in Madrid.
- Published
- 2022
- Full Text
- View/download PDF
6. Infection fatality risk for SARS-CoV-2 in community dwelling population of Spain : nationwide seroepidemiological study
- Author
-
ENE-COVID Study Group, Pastor-Barriuso, Roberto, Pérez-Gómez, Beatriz, Hernán, Miguel A, Pérez-Olmeda, Mayte, Yotti, Raquel, Oteo-Iglesias, Jesús, Sanmartín, Jose L, León-Gómez, Inmaculada, Fernández-García, Aurora, Fernández-Navarro, Pablo, Cruz, Israel, Martín, Mariano, Delgado-Sanz, Concepción, de Larrea, Nerea Fernández, Paniagua, Jose León, Muñoz-Montalvo, Juan F, Blanco, Faustino, Larrauri, Amparo, and Pollán, Marina
- Published
- 2020
7. Estimated Impact of Nirsevimab on the Incidence of Respiratory Syncytial Virus Infections Requiring Hospital Admission in Children < 1 Year, Weeks 40, 2023, to 8, 2024, Spain.
- Author
-
Mazagatos, Clara, Mendioroz, Jacobo, Rumayor, Mercedes Belén, Gallardo García, Virtudes, Álvarez Río, Virginia, Cebollada Gracia, Ana Delia, Batalla Rebollo, Noa, Barranco Boada, María Isabel, Pérez‐Martínez, Olaia, Lameiras Azevedo, Ana Sofía, López González‐Coviella, Nieves, Castrillejo, Daniel, Fernández Ibáñez, Ana, Giménez Duran, Jaume, Ramírez Córcoles, Cristina, Ramos Marín, Violeta, Larrauri, Amparo, Monge, Susana, Basile, Luca, and García Comas, Luis
- Subjects
RESPIRATORY syncytial virus infections ,HOSPITAL admission & discharge ,CHILDREN'S hospitals ,HUMAN metapneumovirus infection ,RESPIRATORY infections - Abstract
Background: Data from the sentinel surveillance system of severe acute respiratory infections in Spain were used to estimate the impact of administration of nirsevimab to children born from 1 April 2023 onwards. Methods: Estimated RSV hospitalisations in < 1‐year‐olds during weeks 40, 2023, to 8, 2024, were compared to the number that would be expected after accounting for the background change in RSV circulation in the 2023/24 season, compared to 2022/23. Results: We estimated 9364–9875 RSV hospitalisations less than expected, corresponding to a 74%–75% reduction. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. Effectiveness of influenza vaccine against influenza A in Europe in seasons of different A(H1N1)pdm09 and the same A(H3N2) vaccine components (2016–17 and 2017–18)
- Author
-
Kissling, Esther, Pozo, Francisco, Buda, Silke, Vilcu, Ana-Maria, Rizzo, Caterina, Gherasim, Alin, Horváth, Judit Krisztina, Brytting, Mia, Domegan, Lisa, Meijer, Adam, Paradowska-Stankiewicz, Iwona, Machado, Ausenda, Vučina, Vesna Višekruna, Lazar, Mihaela, Johansen, Kari, Dürrwald, Ralf, van der Werf, Sylvie, Bella, Antonino, Larrauri, Amparo, Ferenczi, Annamária, Zakikhany, Katherina, O'Donnell, Joan, Dijkstra, Frederika, Bogusz, Joanna, Guiomar, Raquel, Filipović, Sanja Kurečić, Pitigoi, Daniela, Penttinen, Pasi, and Valenciano, Marta
- Published
- 2019
- Full Text
- View/download PDF
9. Illness Severity in Hospitalized Influenza Patients by Virus Type and Subtype, Spain, 2010-2017
- Author
-
Delgado-Sanz, Concepcion, Mazagatos-Ateca, Clara, Oliva, Jesus, Gherasim, Alin, and Larrauri, Amparo
- Subjects
Obesity -- Analysis ,Influenza viruses -- Analysis ,Hospital patients -- Analysis ,Influenza -- Analysis ,Adult respiratory distress syndrome -- Analysis ,Intelligence gathering ,Respiratory distress syndrome ,Diseases ,Health - Abstract
During the 2009 influenza pandemic, influenza surveillance activities were intensified in Spain (1). In accordance with international recommendations (2), Spain established surveillance of Severe Hospitalized Confirmed Influenza Case-patients (SHCIC) to [...]
- Published
- 2020
- Full Text
- View/download PDF
10. Repeated seasonal influenza vaccination among elderly in Europe: Effects on laboratory confirmed hospitalised influenza
- Author
-
Rondy, Marc, Launay, Odile, Castilla, Jesus, Costanzo, Simona, Puig-Barberà, Joan, Gefenaite, Giedre, Larrauri, Amparo, Rizzo, Caterina, Pitigoi, Daniela, Syrjänen, Ritva K., Machado, Ausenda, Kurečić Filipović, Sanja, Krisztina Horváth, Judit, Paradowska-Stankiewicz, Iwona, Marbus, Sierk, and Moren, Alain
- Published
- 2017
- Full Text
- View/download PDF
11. Evaluating the impact of the weather conditions on the influenza propagation
- Author
-
Singh, David E., Marinescu, Maria-Cristina, Carretero, Jesus, Delgado-Sanz, Concepcion, Gomez-Barroso, Diana, and Larrauri, Amparo
- Published
- 2020
- Full Text
- View/download PDF
12. Impact of national influenza vaccination strategy in severe influenza outcomes among the high-risk Portuguese population
- Author
-
Machado, Ausenda, Kislaya, Irina, Larrauri, Amparo, Matias Dias, Carlos, and Nunes, Baltazar
- Published
- 2019
- Full Text
- View/download PDF
13. Waning protection of influenza vaccine against mild laboratory confirmed influenza A(H3N2) and B in Spain, season 2014–15
- Author
-
Gherasim, Alin, Pozo, Francisco, de Mateo, Salvador, Aspiritxaga Gamarra, Inma, García-Cenoz, Manuel, Vega, Tomas, Martínez, Eva, Giménez, Jaume, Castrillejo, Daniel, and Larrauri, Amparo
- Published
- 2016
- Full Text
- View/download PDF
14. Effectiveness of a Second Dose of an mRNA Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Omicron Infection in Individuals Previously Infected by Other Variants
- Author
-
Monge Corella, Susana, Rojas-Benedicto, Ayelén, Olmedo, Carmen, Martín-Merino, Elisa, Mazagatos, Clara, Limia, Aurora, Sierra, María José, Larrauri, Amparo, Hernán, Miguel A, IBERCovid, and Gomez-Barroso, Diana
- Subjects
Microbiology (medical) ,Vaccines ,Infectious Diseases ,Omicron ,SARS-CoV-2 ,Reinfection ,COVID-19 ,Humans ,Effectiveness ,BNT162 Vaccine ,2019-nCoV Vaccine mRNA-1273 - Abstract
Background Single-dose vaccination was widely recommended in the pre-Omicron era for persons with previous SARS-CoV-2 infection. The effectiveness of a second vaccine dose in this group in the Omicron era is unknown. Methods We linked nationwide population registries in Spain to identify community-dwelling individuals aged 18–64, with a positive SARS-CoV-2 test before single-dose mRNA vaccination (mRNA-1273 or BNT162b2). Every day between 3 January and 6 February 2022 we matched 1:1 individuals receiving a second mRNA vaccine dose and controls on sex, age, province, first dose type and time, month of primary infection, and number of previous tests. We then estimated Kaplan–Meier risks of confirmed SARS-CoV-2 reinfection. We performed a similar analysis in a Delta-dominant period, between 19 July and 30 November 2021. Results In the Omicron period, estimated effectiveness (95% CI) of a second dose was 62.2% (58.2–66.4%) 7–34 days after administration, similar across groups defined by age, sex, type of first vaccine, and time since the first dose. Estimated effectiveness was 65.4% (61.1–69.9%) for mRNA-1273 and 52.0% (41.8–63.1%) for BNT162b2. Estimated effectiveness was 78.5% (67.4–89.9%), 66.1% (54.9–77.5%), and 60.2% (55.5–64.8%) when primary infection had occurred in the Delta, Alpha, and pre-Alpha periods, respectively. In the Delta period, the estimated effectiveness of a second dose was 8.8% (−55.3% to 81.1%). Conclusions Our results suggest that, over 1 month after administration, a second dose of mRNA vaccine increases protection against SARS-CoV-2 reinfection with the Omicron variant among individuals with single-dose vaccination and previously infected with another variant.
- Published
- 2023
15. Impact of Rapid On-demand Molecular Diagnosis of Pediatric Seasonal Influenza on Laboratory Workflow and Testing Costs: A Retrospective Study
- Author
-
Brotons, Pedro, Nogueras, Maria-Mercedes, Valls, Ana, Larrauri, Amparo, Dominguez, Angela, Launes, Cristian, Luaces-Cubells, Carlos, and Muñoz-Almagro, Carmen
- Published
- 2019
- Full Text
- View/download PDF
16. Effect of neuraminidase inhibitor (oseltamivir) treatment on outcome of hospitalised influenza patients, surveillance data from 11 EU countries, 2010 to 2020
- Author
-
Adlhoch, Cornelia, Delgado-Sanz, Concepción, Carnahan, AnnaSara, Larrauri, Amparo, Popovici, Odette, Bossuyt, Nathalie, Thomas, Isabelle, Kynčl, Jan, Slezak, Pavel, Brytting, Mia, Guiomar, Raquel, Redlberger-Fritz, Monika, Maistre Melillo, Jackie, Melillo, Tanya, van Gageldonk-Lafeber, Arianne B, Marbus, Sierk D, O'Donnell, Joan, Domegan, Lisa, Gomes Dias, Joana, and Olsen, Sonja J
- Subjects
fatal outcome ,antiviral treatment ,surveillance ,risk factors ,epidemiology ,clinic ,hospital ,EU ,Influenza ,influenza virus - Published
- 2023
17. Direct and Indirect Effectiveness of mRNA Vaccination against Severe Acute Respiratory Syndrome Coronavirus 2 in Long-Term Care Facilities, Spain
- Author
-
Monge, Susana, Olmedo, Carmen, Alejos, Belén, Lapeña, María Fé, Sierra, María José, Limia, Aurora, COVID-19 Registries Study Group2, Mazagatos, Clara, and Larrauri, Amparo
- Subjects
Epidemiology ,Infectious and parasitic diseases ,RC109-216 ,Cohort Studies ,Elderly ,Zoonoses ,Severe acute respiratory syndrome coronavirus 2 ,Direct and Indirect Effectiveness of mRNA Vaccination against Severe Acute Respiratory Syndrome Coronavirus 2 in Long-Term Care Facilities, Spain ,Vaccine effectiveness ,education.field_of_study ,Incidence (epidemiology) ,Vaccination ,Coronavirus disease ,Care facility ,Indirect effects ,Infectious Diseases ,coronavirus disease ,Viruses ,Medicine ,Cohort study ,severe acute respiratory syndrome coronavirus 2 ,Microbiology (medical) ,medicine.medical_specialty ,COVID-19 Vaccines ,Coronavirus disease 2019 (COVID-19) ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Population ,elderly ,long-term care facilities ,respiratory infections ,Internal medicine ,parasitic diseases ,medicine ,Humans ,transmissibility ,viruses ,RNA, Messenger ,education ,BNT162 Vaccine ,indirect effects ,vaccine effectiveness ,Long-term care facilities ,Transmissibility ,business.industry ,SARS-CoV-2 ,Research ,Respiratory infections ,COVID-19 ,Long-Term Care ,zoonoses ,Long-term care ,Spain ,business - Abstract
We conducted a registries-based cohort study of long-term care facility residents >65 years of age offered vaccination against severe acute respiratory syndrome coronavirus 2 before March 10, 2021, in Spain. Risk for infection in vaccinated and nonvaccinated persons was compared with risk in the same persons in a period before the vaccination campaign, adjusted by daily-varying incidence and reproduction number. We selected 299,209 persons; 99.0% had >1 dose, 92.6% had 2 doses, and 99.8% of vaccines were Pfizer/BioNTech (BNT162b2). For vaccinated persons with no previous infection, vaccine effectiveness was 81.8% (95% CI 81.0%-82.7%), and 11.6 (95% CI 11.3-11.9) cases were prevented per 10,000 vaccinated/day. In those with previous infection, effectiveness was 56.8% (95% CI 47.1%-67.7%). In nonvaccinated residents with no previous infection, risk decreased by up to 81.4% (95% CI 73.3%-90.3%). Our results confirm vaccine effectiveness in this population and suggest indirect protection in nonvaccinated persons. Sí
- Published
- 2021
18. Higher vaccine effectiveness in seasons with predominant circulation of seasonal influenza A(H1N1) than in A(H3N2) seasons: Test-negative case-control studies using surveillance data, Spain, 2003-2011
- Author
-
Savulescu, Camelia, Jiménez-Jorge, Silvia, Delgado-Sanz, Concha, de Mateo, Salvador, Pozo, Francisco, Casas, Inmaculada, and Larrauri, Amparo
- Published
- 2014
- Full Text
- View/download PDF
19. Impact of Influenza Vaccination on the Burden of Severe Influenza in the Elderly: Spain, 2017–2020.
- Author
-
Mazagatos, Clara, Delgado-Sanz, Concepción, Milagro, Ana, Liébana-Rodríguez, María, and Larrauri, Amparo
- Subjects
INFLUENZA vaccines ,INFLUENZA ,SEASONAL influenza ,OLDER people ,VACCINE effectiveness ,SEASONAL variations of diseases ,MEDICALLY unexplained symptoms - Abstract
Annual influenza vaccination is the main strategy to reduce the burden of seasonal influenza epidemics and is recommended for the elderly in most countries with influenza vaccination strategies, with the main objective of preventing hospitalizations and mortality associated with seasonal influenza in this age group. Studies from different countries have estimated the benefits of seasonal influenza vaccination programs in the elderly, preventing a considerable number of cases, hospitalizations and deaths every year. A study measured the number of medically attended confirmed influenza cases in primary care that are prevented annually by vaccination in the population aged 65 and older in Spain, the Netherlands and Portugal, but estimates of the impact of the national influenza vaccination program in the prevention of severe disease in Spain are lacking. The two objectives of this study were to estimate the burden of severe influenza disease in the Spanish population and to measure the impact of influenza vaccination in the prevention of these outcomes in the population aged 65 years and older. Using influenza surveillance systems put in place before the COVID-19 pandemic, we conducted a retrospective observational study to estimate the burden of hospitalizations and ICU admissions in Spain between 2017–18 and 2019–20, by season and age group. Burden estimates for the 65+ group, combined with vaccine effectiveness (VE) and vaccination coverage (VC) data, were used as input data in an ecological, observational study to estimate the impact of the influenza vaccination program on the elderly. We found a higher burden of severe influenza disease in seasons 2017–18 and 2018–19, with A(H3N2) circulation, and in the youngest and oldest age groups. In those aged 65 and older, we estimated an average of 9900 influenza hospitalizations and 1541 ICU admissions averted by vaccination each year. Seasonal influenza vaccination was able to prevent between 11 and 26% influenza hospitalizations and around 40% ICU admissions in the elderly in the three pre-pandemic seasons. In conclusion, our study complements previous analyses in the primary care setting in Spain and demonstrates the benefits of the annual influenza vaccination program in the prevention of severe influenza disease in the elderly, even in seasons with moderate VE. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
20. Rapidly adapting primary care sentinel surveillance across seven countries in Europe for COVID-19 in the first half of 2020: strengths, challenges, and lessons learned
- Author
-
Bagaria, Jayshree, Jansen, Tessa, Marques, Diogo Fp, Hooiveld, Mariette, McMenamin, Jim, de Lusignan, Simon, Vilcu, Ana-Maria, Meijer, Adam, Rodrigues, Ana-Paula, Brytting, Mia, Mazagatos, Clara, Cogdale, Jade, van der Werf, Sylvie, Dijkstra, Frederika, Guiomar, Raquel, Enkirch, Theresa, Valenciano, Marta, I-MOVE-COVID-19 study team, Larrauri, Amparo, Pozo Sanchez, Francisco, Casas Flecha, Inmaculada, Unión Europea. Comisión Europea. H2020, Public Health Scotland [Glasgow], Netherlands Institute for Health Services Research [Utrecht] (NIVEL), EpiConcept [Paris], University of Oxford, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), National Institute for Public Health and the Environment [Bilthoven] (RIVM), Instituto Nacional de Saùde Dr Ricardo Jorge [Portugal] (INSA), Public Health Agency of Sweden, Institute of Health Carlos III, UK Health Security Agency (UKHSA), Génétique Moléculaire des Virus à ARN - Molecular Genetics of RNA Viruses (GMV-ARN (UMR_3569 / U-Pasteur_2)), Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Centre National de Référence des virus des infections respiratoires (dont la grippe) - National Reference Center Virus Influenzae [Paris] (CNR), Institut Pasteur [Paris] (IP)-Université Paris Cité (UPCité), This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101003673., MOVE-COVID-19 study team: Esther Kissling, Lisa Domegan, Joan O'Donnell, Josephine Murray, Virginia Sandonis Martín, Iván Martínez-Baz, Ausenda Machado, Itziar Casado, Sylvie Behillil, Amparo Larrauri, Ruby Tsang, Marit de Lange, Maximilian Riess, Jesús Castilla, Mark Hamilton, Alessandra Falchi, Francisco Pozo, Linda Dunford, Cristina Burgui, Debbie Sigerson, Thierry Blanchon, Eva María Martínez Ochoa, Jeff Connell, Joanna Ellis, Rianne van Gageldonk-Lafeber, Irina Kislaya, Angela Mc Rose, Jamie Lopez Bernal, Nick Andrews, Inmaculada Casas Flecha, Janine Thoulass, Baltazar Nunes, Verónica Gomez, Rita Sa Machado, Vincent Enouf, Pedro Licinio Pinto Leite, Anna Molesworth, Adele McKenna, Janine Thoulass, European Project: 101003673,H2020-SC1-PHE-CORONAVIRUS-2020,I-MOVE-COVID-19(2020), HAL-SU, Gestionnaire, Multidisciplinary European network for research, prevention and control of the COVID-19 Pandemic - I-MOVE-COVID-19 - - H2020-SC1-PHE-CORONAVIRUS-20202020-03-16 - 2022-06-15 - 101003673 - VALID, UK Health Security Agency [London] (UKHSA), and Centre National de Référence des virus des infections respiratoires (dont la grippe) - National Reference Center Virus Influenzae [Paris] (CNR - laboratoire coordonnateur)
- Subjects
Epidemiology ,Sentinel surveillance ,primary care ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,Virology ,Influenza, Human ,Humans ,Influenza-Like Illness ,Pandemics ,[SDV.MHEP.ME] Life Sciences [q-bio]/Human health and pathology/Emerging diseases ,[SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases ,Primary Health Care ,SARS-CoV-2 ,Cuidados de Saúde ,Public Health, Environmental and Occupational Health ,Influenza-Like Illness (ILI) ,COVID-19 ,Estados de Saúde e de Doença ,Primary care ,Europe ,Vigilância Epidemiológica ,[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie ,Influenza Vaccines ,[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,Sentinel Surveillance - Abstract
I-MOVE-COVID-19 study team: Esther Kissling, Lisa Domegan, Joan O’Donnell, Josephine Murray, Virginia Sandonis Martín, Iván Martínez-Baz, Ausenda Machado, Itziar Casado, Sylvie Behillil, Amparo Larrauri, Ruby Tsang, Marit de Lange, Maximilian Riess, Jesús Castilla, Mark Hamilton, Alessandra Falchi, Francisco Pozo, Linda Dunford, Cristina Burgui, Debbie Sigerson, Thierry Blanchon, Eva María Martínez Ochoa, Jeff Connell, Joanna Ellis, Rianne van Gageldonk-Lafeber, Irina Kislaya, Angela MC Rose, Jamie Lopez Bernal, Nick Andrews, Inmaculada Casas Flecha, Janine Thoulass, Baltazar Nunes, Verónica Gomez, Rita Sa Machado, Vincent Enouf, Pedro Licinio Pinto Leite, Anna Molesworth, Adele McKenna, Janine Thoulass As the COVID-19 pandemic began in early 2020, primary care influenza sentinel surveillance networks within the Influenza - Monitoring Vaccine Effectiveness in Europe (I-MOVE) consortium rapidly adapted to COVID-19 surveillance. This study maps system adaptations and lessons learned about aligning influenza and COVID-19 surveillance following ECDC / WHO/Europe recommendations and preparing for other diseases possibly emerging in the future. Using a qualitative approach, we describe the adaptations of seven sentinel sites in five European Union countries and the United Kingdom during the first pandemic phase (March–September 2020). Adaptations to sentinel systems were substantial (2/7 sites), moderate (2/7) or minor (3/7 sites). Most adaptations encompassed patient referral and sample collection pathways, laboratory testing and data collection. Strengths included established networks of primary care providers, highly qualified testing laboratories and stakeholder commitments. One challenge was the decreasing number of samples due to altered patient pathways. Lessons learned included flexibility establishing new routines and new laboratory testing. To enable simultaneous sentinel surveillance of influenza and COVID-19, experiences of the sentinel sites and testing infrastructure should be considered. The contradicting aims of rapid case finding and contact tracing, which are needed for control during a pandemic and regular surveillance, should be carefully balanced. This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101003673. info:eu-repo/semantics/publishedVersion
- Published
- 2022
21. Effectiveness of complete primary vaccination against COVID-19 at primary care and community level during predominant Delta circulation in Europe: multicentre analysis, I-MOVE-COVID-19 and ECDC networks, July to August 2021
- Author
-
Kissling, Esther, Hooiveld, Mariëtte, Martínez-Baz, Iván, Mazagatos, Clara, William, Naoma, Vilcu, Ana-Maria, Kooijman, Marjolein N, Ilić, Maja, Domegan, Lisa, Machado, Ausenda, de Lusignan, Simon, Lazar, Mihaela, Meijer, Adam, Brytting, Mia, Casado, Itziar, Larrauri, Amparo, Murray, Josephine-L K, Behillil, Sylvie, de Gier, Brechje, Mlinarić, Ivan, O'Donnell, Joan, Rodrigues, Ana Paula, Tsang, Ruby, Timnea, Olivia, de Lange, Marit, Riess, Maximilian, Castilla, Jesús, Pozo Sanchez, Francisco, Hamilton, Mark, Falchi, Alessandra, Knol, Mirjam J, Kurečić Filipović, Sanja, Dunford, Linda, Guiomar, Raquel, Cogdale, Jade, Cherciu, Carmen, Jansen, Tessa, Enkirch, Theresa, Basile, Luca, Connell, Jeff, Gomez, Verónica, Sandonis-Martin, Virginia, Bacci, Sabrina, Rose, Angela Mc, Pastore Celentano, Lucia, Valenciano, Marta, I-MOVE-COVID-19, ECDC primary care study teams, Conde-San Román, Patricia, Casas Flecha, Inmaculada, Oliva Dominguez, Jesus Angel, Delgado-Sanz, Concepcion, EpiConcept [Paris], Netherlands Institute for Health Services Research [Utrecht] (NIVEL), Navarra Institute for Health Research / Instituto de Investigación Sanitaria de Navarra (IdiSNA), Universidad Pública de Navarra [Espagne] = Public University of Navarra (UPNA)-Universidad de Navarra [Pamplona] (UNAV)-Clínica Universidad de Navarra [Pamplona], CIBER de Epidemiología y Salud Pública (CIBERESP), Institute of Health Carlos III, Public Health Scotland [Glasgow], Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), National Institute for Public Health and the Environment [Bilthoven] (RIVM), Croatian Institute of Public Health [Zagreb] (CIPH), Health Service Executive [Dublin] (HSE), Instituto Nacional de Saùde Dr Ricardo Jorge [Portugal] (INSA), University of Oxford, Cantacuzino Institute [Romania], Réseau International des Instituts Pasteur (RIIP), Public Health Agency of Sweden, Instituto de Salud Carlos III [Madrid] (ISC), Centre National de Référence des virus des infections respiratoires (dont la grippe) - National Reference Center Virus Influenzae [Paris] (CNR - laboratoire coordonnateur), Institut Pasteur [Paris] (IP)-Université Paris Cité (UPCité), Biologie des ARN et virus influenza - RNA Biology of Influenza Virus (CNRS-UMR3569), Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), University College Dublin [Dublin] (UCD), UK Health Security Agency [London] (UKHSA), European Centre for Disease Prevention and Control [Stockholm, Sweden] (ECDC), I-MOVE-COVID-19 and ECDC primary care study team Katica Čusek Adamić, Ivana Ferenčak, Bernard Kaić, Mirjana Lana Kosanović Ličina, Danijela Lakošeljac, Ivana Mihin Huskić, Diana Nonković, Nick Andrews, Jamie Lopez Bernal, Joanna Ellis, Heather Whitaker, Thierry Blanchon, Caroline Guerrisi, Titouan Launay, Shirley Masse, Sylvie van der Werf, Vincent Enouf, John Cuddihy, Lois O'Connor, Adele McKenna, Michael Joyce, Cillian de Gascun, Joanne Moran, Rianne van Gageldonk-Lafeber, Susan J Hahné, Hester E de Melker, Ewout B Fanoy, Stijn Raven, Marit Middeldorp, Irina Kislaya, Baltazar Nunes, Rita Roquete, Adriana Silva, Aryse Melo, Inês Costa, Nuno Verdasca, Patrícia Conde, Amélia Soeiro, Maria Elena Mihai, Iulia Bistriceanu, Alina Ivanciuc, Diana Dintoi, Catalina Pascu, Adrian Jidovu, Debbie Sigerson, Diogo Fp Marques, Anna Molesworth, Leanne Quinn, Miranda Leyton, Selin Campbell, Janine Thoulass, Jim McMenamin, Inmaculada Casas Flecha, Ana Martínez Mateo, Daniel Castrillejo, Eva María Martínez Ochoa, Carmen Quiñones Rubio, Concepción Delgado-Sanz, Jesús Oliva, Ana Miqueleiz, Ana Navascués, Camino Trobajo-Sanmartín, Carmen Ezpeleta, Paula López Moreno, Javier Gorricho, Eva Ardanaz, Fernando Baigorria, Aurelio Barricarte, Cristina Burgui, Enrique de la Cruz, Nerea Egüés, Manuel García Cenoz, Marcela Guevara, Conchi Moreno-Iribas, Carmen Sayón, Pasi Penttinen, Christiana Carstairs, University of St Andrews. School of Medicine, Unión Europea. Comisión Europea. H2020, and European Centre for Disease Prevention and Control
- Subjects
Test-negative design ,RM ,Delta variant ,COVID-19 Vaccines ,Epidemiology ,[SDV]Life Sciences [q-bio] ,Multicentre study ,Influenza, Human/prevention & control ,MESH: Primary Health Care ,Europe/epidemiology ,MESH: Influenza Vaccines ,SDG 3 - Good Health and Well-being ,RA0421 ,RA0421 Public health. Hygiene. Preventive Medicine ,Virology ,Influenza, Human ,Humans ,MESH: COVID-19 ,MESH: SARS-CoV-2 ,COVID-19/epidemiology ,Vaccine effectiveness ,QR355 ,MESH: Humans ,Primary Health Care ,vaccine effectiveness ,SARS-CoV-2 ,MESH: Influenza, Human ,Vaccination ,test-negative design ,Public Health, Environmental and Occupational Health ,COVID-19 ,3rd-DAS ,MESH: Vaccination ,NIS ,multicentre study ,RM Therapeutics. Pharmacology ,Europe ,Influenza Vaccines ,MESH: COVID-19 Vaccines ,SARS-COV-2 ,vaccine efffectiveness ,MESH: Europe ,QR355 Virology - Abstract
Introduction In July and August 2021, the SARS-CoV-2 Delta variant dominated in Europe. Aim Using a multicentre test-negative study, we measured COVID-19 vaccine effectiveness (VE) against symptomatic infection. Methods Individuals with COVID-19 or acute respiratory symptoms at primary care/community level in 10 European countries were tested for SARS-CoV-2. We measured complete primary course overall VE by vaccine brand and by time since vaccination. Results Overall VE was 74% (95% CI: 69–79), 76% (95% CI: 71–80), 63% (95% CI: 48–75) and 63% (95% CI: 16–83) among those aged 30–44, 45–59, 60–74 and ≥ 75 years, respectively. VE among those aged 30–59 years was 78% (95% CI: 75–81), 66% (95% CI: 58–73), 91% (95% CI: 87–94) and 52% (95% CI: 40–61), for Comirnaty, Vaxzevria, Spikevax and COVID-19 Vaccine Janssen, respectively. VE among people 60 years and older was 67% (95% CI: 52–77), 65% (95% CI: 48–76) and 83% (95% CI: 64–92) for Comirnaty, Vaxzevria and Spikevax, respectively. Comirnaty VE among those aged 30–59 years was 87% (95% CI: 83–89) at 14–29 days and 65% (95% CI: 56–71%) at ≥ 90 days between vaccination and onset of symptoms. Conclusions VE against symptomatic infection with the SARS-CoV-2 Delta variant varied among brands, ranging from 52% to 91%. While some waning of the vaccine effect may be present (sample size limited this analysis to only Comirnaty), protection was 65% at 90 days or more between vaccination and onset.
- Published
- 2022
22. Four-month incidence of suicidal thoughts and behaviors among healthcare workers after the first wave of the Spain COVID-19 pandemic
- Author
-
Alonso, Jordi, Alayo, Itxaso, Alonso, Manuel, Álvarez, Mar, Amann, Benedikt, Amigo, Franco F., Anmella, Gerard, Aragón, Andres, Aragonés, Nuria, Aragonès, Enric, Arizón, Ana Isabel, Asunsolo, Angel, Ayora, Alfons, Ballester, Laura, Barbas, Puri, Basora, Josep, Bereciartua, Elena, Ignasi Bolibar, Inés Bravo, Bonfill, Xavier, Cotillas, Alberto, Cuartero, Andres, de Paz, Concha, Cura, Isabel del, Jesus del Yerro, Maria, Diaz, Domingo, Domingo, Jose Luis, Emparanza, Jose I., Espallargues, Mireia, Espuga, Meritxell, Estevan, Patricia, Fernandez, M. Isabel, Fernandez, Tania, Ferrer, Montse, Ferreres, Yolanda, Fico, Giovanna, Forjaz, M. Joao, Barranco, Rosa Garcia, Garcia TorrecillasC Garcia-Ribera, J. Manuel, Garrido, Araceli, Gil, Elisa, Gomez, Marta, Gomez, Javier, Pinto, Ana Gonzalez, Haro, Josep Maria, Hernando, Margarita, Insigna, Maria Giola, Iriberri, Milagros, Jimenez, Nuria, Jimenez, Xavi, Larrauri, Amparo, Leon, Fernando, Lopez-Fresneña, Nieves, Lopez, Carmen, Lopez-Atanes Juan Antonio Lopez-Rodriguez, Mayte, Lopez-Cortacans, German, Marcos, Alba, Martin, Jesus, Martin, Vicente, Martinez-Cortés, Mercedes, Martinez-Martinez, Raquel, Martinez de Salazar, Alma D., Martinez, Isabel, Marzola, Marco, Mata, Nelva, Molina, Josep Maria, de Dios Molina, Juan, Molinero, Emilia, Mortier, Philippe, Muñoz, Carmen, Murru, Andrea, Olmedo, Jorge, Ortí, Rafael M., Padrós, Rafael, Pallejà, Meritxell, Parra, Raul, Pascual, Julio, Pelayo, Jose Maria, Pla, Rosa, Plana, Nieves, Aznar, Coro Perez, Gomez, Beatriz Perez, Zapata, Aurora Perez, Pijoan, Jose Ignacio, Polentinos, Elena, Puertolas, Beatriz, Puig, Maria Teresa, Quílez, Alex, Quintana, M. Jesus, Quiroga, Antonio, Rentero, David, Rey, Cristina, Rius, Cristina, Rodriguez-Blazquez, Carmen, Rojas, M. Jose, Romero, Yamina, Rubio, Gabriel, Rumayor, Mercedes, Ruiz, Pedro, Saenz, Margarita, Sanchez, Jesus, Sanchez-Arcilla, Ignacio, Sanz, Ferran, Serra, Consol, Serra-Sutton, Victoria, Serrano, Manuela, Sola, Silvia, Solera, Sara, Soto, Miguel, Tarrago, Alejandra, Tolosa, Natividad, Vazquez, Mireia, Viciola, Margarita, Vieta, Eduard, Vilagut, Gemma, Yago, Sara, Yañez, Jesus, Zapico, Yolanda, Zorita, Luis Maria, Zorrilla, Iñaki, Zurbano, Saioa L., Perez-Solá, Victor, Mortier, P., Vilagut, G., Alayo, I., Ferrer, M., Amigo, F., Aragonès, E., Aragón-Peña, A., Asúnsolo del Barco, A., Campos, M., Espuga, M., González-Pinto, A., Haro, J.M., López Fresneña, N., Martínez de Salázar, A., Molina, J.D., Ortí-Lucas, R.M., Parellada, M., Pelayo-Terán, J.M., Pérez-Gómez, B., Pérez-Zapata, A., Pijoan, J.I., Plana, N., Polentinos-Castro, E., Portillo-Van Diest, A., Puig, M.T., Rius, C., Sanz, F., Serra, C., Urreta-Barallobre, I., Kessler, R.C., Bruffaerts, R., Vieta, E., Pérez-Solá, V., and Alonso, J.
- Published
- 2022
- Full Text
- View/download PDF
23. Effectiveness of a Second Dose of an mRNA Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Omicron Infection in Individuals Previously Infected by Other Variants.
- Author
-
Monge, Susana, Rojas-Benedicto, Ayelén, Olmedo, Carmen, Martín-Merino, Elisa, Mazagatos, Clara, Limia, Aurora, Sierra, María José, Larrauri, Amparo, Hernán, Miguel A, and IBERCovid
- Subjects
DRUG efficacy ,COVID-19 ,IMMUNIZATION ,CONFIDENCE intervals ,COVID-19 vaccines ,REINFECTION ,TREATMENT effectiveness ,MESSENGER RNA ,INDEPENDENT living ,KAPLAN-Meier estimator ,EVALUATION - Abstract
Background Single-dose vaccination was widely recommended in the pre-Omicron era for persons with previous SARS-CoV-2 infection. The effectiveness of a second vaccine dose in this group in the Omicron era is unknown. Methods We linked nationwide population registries in Spain to identify community-dwelling individuals aged 18–64, with a positive SARS-CoV-2 test before single-dose mRNA vaccination (mRNA-1273 or BNT162b2). Every day between 3 January and 6 February 2022 we matched 1:1 individuals receiving a second mRNA vaccine dose and controls on sex, age, province, first dose type and time, month of primary infection, and number of previous tests. We then estimated Kaplan–Meier risks of confirmed SARS-CoV-2 reinfection. We performed a similar analysis in a Delta-dominant period, between 19 July and 30 November 2021. Results In the Omicron period, estimated effectiveness (95% CI) of a second dose was 62.2% (58.2–66.4%) 7–34 days after administration, similar across groups defined by age, sex, type of first vaccine, and time since the first dose. Estimated effectiveness was 65.4% (61.1–69.9%) for mRNA-1273 and 52.0% (41.8–63.1%) for BNT162b2. Estimated effectiveness was 78.5% (67.4–89.9%), 66.1% (54.9–77.5%), and 60.2% (55.5–64.8%) when primary infection had occurred in the Delta, Alpha, and pre-Alpha periods, respectively. In the Delta period, the estimated effectiveness of a second dose was 8.8% (−55.3% to 81.1%). Conclusions Our results suggest that, over 1 month after administration, a second dose of mRNA vaccine increases protection against SARS-CoV-2 reinfection with the Omicron variant among individuals with single-dose vaccination and previously infected with another variant. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
24. Influenza-related mortality in Spain, 1999-2005
- Author
-
López-Cuadrado, Teresa, de Mateo, Salvador, Jiménez-Jorge, Silvia, Savulescu, Camelia, and Larrauri, Amparo
- Published
- 2012
- Full Text
- View/download PDF
25. Establishing a novel European hospital surveillance platform in response to a newly emerging infection lessons from the I-MOVE-COVID-19 hospital network
- Author
-
Ladbury, Georgia, Hamilton, Mark, Harvey, Ciaran, Mutch, Heather, McMahon, James, Mokogwu, Damilola, Sadiq, Fatima, Young, Johanna, Wallace, Lesley, Murray, Josie, Lopez‑Bernal, Jamie, Andrews, Nick, Castilla, Jesús, Casado, Itziar, Larrauri, Amparo, Mazagatos, Clara, Duval, Xavier, Bino, Silvia, Demuyser, Thomas, Machado, Ausenda, Mickiene, Aukse, Lazar, Mihaela, Stavaru, Crina, Rath, Barbara, Harrabi, Myriam, Rekacewicz, Claire, Kapisyszi, Perlat, Seyler, Lucie, Gómez, Verónica, Jancoriene, Ligita, and Rose, Angela
- Subjects
Infecções Respiratórias ,Surveillance ,SARS-CoV-2 ,COVID-19 ,Determinantes da Saúde e da Doença ,Hospital Admission ,I-MOVE-COVID-19 - Abstract
Background: The first signal of a new infection is often severe cases presenting at hospital. Enhanced surveillance of these cases is critical to learning more about disease epidemiology and patient outcomes, but nationallevel surveillance can lack power to draw conclusions. In response to the emergence of SARS-CoV-2, the Influenza-Monitoring Vaccine Effectiveness (I-MOVE) network, founded in 2007, expanded to establish the I-MOVE-COVID-19 Consortium in February 2020. The Consortium’s surveillance objectives included using pooled data to describe clinical and epidemiological characteristics of hospitalised COVID-19 patients across Europe, in order to contribute to the knowledge base, guide patient management, and inform public health response. Methods: Eleven study sites participated in the surveillance, including 23 hospitals across six EU Member States and Albania, and hospitals nationally in England and Scotland. A standardised protocol and dataset for collection was agreed by April 2020. In England and Scotland, data were generated by linkage of routine datasets; other sites used bespoke paper or electronic questionnaires. Data were submitted, pooled and analysed quarterly. Results: Data were received regarding 84,297 COVID-19 patients hospitalised between 1 February 2020 and 31 January 2021. Three surveillance bulletins were published between September 2020 and March 2021, providing key insights into severe COVID-19 at European level. However, the unexpected, overwhelming workload at participating sites, and difficulties securing data protection and ethics permissions, delayed data submissions and presented challenges for timely analysis. Conclusions: Building on an existing network facilitated a novel European multicentre hospital surveillance system to be implemented during a pandemic; however, timeliness was nonetheless problematic. In future, processes could be streamlined e.g. by developing pre-approved template protocols with information governance and ethical approvals in place during the inter- pandemic period. The I-MOVE-COVID-19 network has received funding from the European Commission (from the European Union’s Horizon 2020 research and innovation programme under grant agreement no. 101003673). N/A
- Published
- 2021
26. Enhanced surveillance of COVID-19 in secondary care in Europe: a tale of two waves
- Author
-
Mokogwu, Damilola, Hamilton, Mark, Harvey, Ciaran, Elgohari, Suzanne, Burgui, Cristina, Mazagatos, Clara, Galtier, Florence, Seyler, Lucie, Machado, Ausenda, Jonikaite, Indre, Lazar, Mihaela, Rath, Barbara, Mutch, Heather, McMahon, James, Ladbury, Georgia, Akinnawo, Ayodele, Martínez-Baz, Iván, Larrauri, Amparo, Laine, Fabrice, Fico, Albana, Demuyser, Thomas, Kislaya, Irina, Gefenaite, Giedre, Cherciu, Carmen, Harrabi, Myriam, MC Rose, Angela, and I-MOVE study group
- Subjects
Infecções Respiratórias ,Europezc ,COVID-19 ,Estados de Saúde e de Doença ,Epidemiologic Surveillance ,Hospital Admissions ,I-MOVE-COVID-19 - Abstract
Background: The I-MOVE-COVID-19 Consortium was established to conduct surveillance of hospitalised COVID-19 cases in nine European countries, aiming to describe the clinical and epidemiological characteristics of severe COVID-19 in order to inform public health response. Methods: Data are pooled from 11 participating sites; two (England and Scotland) submitting national data, with the remainder being from a selection of hospitals. Descriptive analysis is performed on the pooled dataset overall and comparing data on patients admitted from week 5 to 28 of 2020 (“first wave”) vs those admitted later (“second wave”). Results: Data on 84,297 hospitalised patients were submitted for 01 February 2020 - 31 January 2021. Fifty-six percent of cases (46,907/84,193) were male and median age was 69 years. Where information was available, 44% (25,344 /57,769) patients were recorded as having at least one chronic condition. Ninety-five percent (7,868/8,270 and 90% (5,606/6,231) were reported with respiratory and febrile presentations respectively. Twenty-four percent (18,795/78,955) were admitted to intensive care units (ICU) and 26% (19,805/76,764) died in hospital (all sites); 12% (3,305/28,262) and 20% (5,454/27,066) respectively for all sites except England (where ICU reporting is mandated, biasing the dataset towards more severe outcomes as this site represents >50% of all cases). As a percentage of all hospital admissions, both ICU admissions and deaths decreased significantly between the first and second waves in both sexes and across all age- groups, apart from the over 75s. Conclusions: Results from this multicentre European surveillance system suggest that about one in 10 hospitalised COVID-19 patients are admitted to ICU and one in five have fatal outcomes. Fatality and ICU admission were lower in the second wave compared with the first. The I-MOVE-COVID-19 network has received funding from the European Commission (from the European Union’s Horizon 2020 research and innovation programme under grant agreement no. 101003673). N/A
- Published
- 2021
27. Influenza pandemic (H1N1) 2009 activity during summer 2009. Effectiveness of the 2008-9 trivalent vaccine against pandemic influenza in Spain
- Author
-
Larrauri, Amparo, Savulescu, Camelia, Jiménez-Jorge, Silvia, Pérez-Breña, Pilar, Pozo, Francisco, Casas, Inmaculada, Ledesma, Juan, and de Mateo, Salvador
- Published
- 2011
- Full Text
- View/download PDF
28. Influenza hospitalisations in Spain between the last influenza and COVID-19 pandemic (2009–2019).
- Author
-
Canelas-Fernández, Javier, Mazagatos, Clara, Delgado-Sanz, Concepción, and Larrauri, Amparo
- Abstract
Knowing the burden of severe disease caused by influenza is essential for disease risk communication, to understand the true impact of vaccination programmes and to guide public health and disease control measures. We estimated the number of influenza-attributable hospitalisations in Spain during the 2010–2011 to 2019–2020 seasons – based on the hospitalisations due to severe acute respiratory infection (SARI) in Spain using the hospital discharge database and virological influenza information from the Spanish Influenza Sentinel Surveillance System (SISSS). The weekly numbers of influenza-attributable hospitalisations were calculated by multiplying the weekly SARI hospitalisations by the weekly influenza virus positivity, obtained from the SISSS in each season, stratified by age group and sex. The influenza-related hospitalisation burden is age-specific and varies significantly by influenza season. People aged 65 and over yielded the highest average influenza-attributable hospitalisation rates per season (615.6 per 100,000), followed by children aged under 5 (251.2 per 100,000). These results provide an essential contribution to influenza control and to improving existing vaccination programmes, as well as to the optimisation and planning of health resources and policies. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
29. Traumatic stress symptoms among Spanish healthcare workers during the COVID-19 pandemic: a prospective study.
- Author
-
Portillo-Van Diest, Ana, Vilagut, Gemma, Alayo, Itxaso, Ferrer, Montse, Amigo, Franco, Amann, Benedikt L., Aragón-Peña, Andrés, Aragonès, Enric, Asúnsolo Del Barco, Ángel, Campos, Mireia, Del Cura-González, Isabel, Espuga, Meritxell, González-Pinto, Ana, Haro, Josep M., Larrauri, Amparo, López-Fresneña, Nieves, Martínez de Salázar, Alma, Molina, Juan D., Ortí-Lucas, Rafael M., and Parellada, Mara
- Subjects
COVID-19 pandemic ,MEDICAL personnel ,POST-traumatic stress ,LONGITUDINAL method ,POST-traumatic stress disorder - Abstract
Aim. To investigate the occurrence of traumatic stress symptoms (TSS) among healthcare workers active during the COVID-19 pandemic and to obtain insight as to which pandemic-related stressful experiences are associated with onset and persistence of traumatic stress. Methods. This is a multicenter prospective cohort study. Spanish healthcare workers (N = 4,809) participated at an initial assessment (i.e., just after the first wave of the Spain COVID-19 pandemic) and at a 4-month follow-up assessment using web-based surveys. Logistic regression investigated associations of 19 pandemic-related stressful experiences across four domains (infection-related, work-related, health-related and financial) with TSS prevalence, incidence and persistence, including simulations of population attributable risk proportions (PARP). Results. Thirty-day TSS prevalence at T1 was 22.1%. Four-month incidence and persistence were 11.6% and 54.2%, respectively. Auxiliary nurses had highest rates of TSS prevalence (35.1%) and incidence (16.1%). All 19 pandemic-related stressful experiences under study were associated with TSS prevalence or incidence, especially experiences from the domains of health-related (PARP range 88.4-95.6%) and work-related stressful experiences (PARP range 76.8-86.5%). Nine stressful experiences were also associated with TSS persistence, of which having patient(s) in care who died from COVID-19 had the strongest association. This association remained significant after adjusting for co-occurring depression and anxiety. Conclusions. TSSs among Spanish healthcare workers active during the COVID-19 pandemic are common and associated with various pandemic-related stressful experiences. Future research should investigate if these stressful experiences represent truly traumatic experiences and carry risk for the development of post-traumatic stress disorder. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
30. Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care : I-MOVE-COVID-19 project, Europe, December 2020 to May 2021
- Author
-
Kissling, Esther, Hooiveld, Mariette, Sandonis Martín, Virginia, Martínez-Baz, Iván, William, Naoma, Vilcu, Ana-Maria, Mazagatos, Clara, Domegan, Lisa, de Lusignan, Simon, Meijer, Adam, Machado, Ausenda, Brytting, Mia, Casado, Itziar, Murray, Josephine-L K., Belhillil, Sylvie, Larrauri, Amparo, O’Donnell, Joan, Tsang, Ruby, de Lange, Marit, Rodrigues, Ana Paula, Riess, Maximilian, Castilla, Jesús, Hamilton, Mark, Falchi, Alessandra, Pozo, Francisco, Dunford, Linda, Cogdale, Jade, Jansen, Tessa, Guiomar, Raquel, Enkirch, Theresa, Burgui, Cristina, Sigerson, Debbie, Blanchon, Thierry, Martínez Ochoa, Eva María, Connell, Jeff, Ellis, Joanna, van Gageldonk-Lafeber, Rianne, Kislaya, Irina, Rose, Angela MC, Valenciano, Marta, Andrews, Nick, Lopez Bernal, Jamie, Whitaker, Heather, Guerrisi, Caroline, Launay, Titouan, Masse, Shirley, van der Werf, Sylvie, Enouf, Vincent, Cuddihy, John, McKenna, Adele, Joyce, Michael, de Gascun, Cillian, Moran, Joanne, Miqueleiz, Ana, Navascués, Ana, Trobajo-Sanmartín, Camino, Ezpeleta, Carmen, Moreno, Paula López, Gorricho, Javier, Ardanaz, Eva, Baigorria, Fernando, Barricarte, Aurelio, de la Cruz, Enrique, Egüés, Nerea, García Cenoz, Manuel, Guevara, Marcela, Moreno-Iribas, Conchi, Sayón, Carmen, Gomez, Verónica, Nunes, Baltazar, Roquete, Rita, Silva, Adriana, Melo, Aryse, Costa, Inês, Verdasca, Nuno, Conde, Patrícia, Marques, Diogo FP, Molesworth, Anna, Quinn, Leanne, Leyton, Miranda, Campbell, Selin, Thoulass, Janine, McMenamin, Jim, Mateo, Ana Martínez, Basile, Luca, Castrillejo, Daniel, Quiñones Rubio, Carmen, Delgado-Sanz, Concepción, Oliva., Jesús, University of St Andrews. School of Medicine, team, I-MOVE-COVID-19 primary care study, above), I-MOVE-COVID-19 primary care study team (in addition to authors, EpiConcept [Paris], Netherlands Institute for Health Services Research [Utrecht] (NIVEL), Instituto de Salud Carlos III [Madrid] (ISC), Navarra Institute for Health Research / Instituto de Investigación Sanitaria de Navarra (IdiSNA), Universidad Pública de Navarra [Espagne] = Public University of Navarra (UPNA)-Universidad de Navarra [Pamplona] (UNAV)-Clínica Universidad de Navarra [Pamplona], CIBER de Epidemiología y Salud Pública (CIBERESP), Public Health Scotland [Glasgow], Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Health Service Executive [Dublin] (HSE), University of Oxford, National Institute for Public Health and the Environment [Bilthoven] (RIVM), Instituto Nacional de Saùde Dr Ricardo Jorge [Portugal] (INSA), Public Health Agency of Sweden, Génétique Moléculaire des Virus à ARN - Molecular Genetics of RNA Viruses (GMV-ARN (UMR_3569 / U-Pasteur_2)), Institut Pasteur [Paris] (IP)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS), Centre National de Référence des virus des infections respiratoires (dont la grippe) - National Reference Center Virus Influenzae [Paris] (CNR - laboratoire coordonnateur), Institut Pasteur [Paris] (IP), Università di Corsica Pasquale Paoli [Université de Corse Pascal Paoli], Partenaires INRAE, Institut National de la Santé et de la Recherche Médicale (INSERM), University College Dublin [Dublin] (UCD), Public Health England [London], Dirección General de Salud Pública, This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101003673., European Project: 101003673,H2020-SC1-PHE-CORONAVIRUS-2020,I-MOVE-COVID-19(2020), and Unión Europea. Comisión Europea. H2020
- Subjects
Infecções Respiratórias ,Adult ,Test-negative design ,2019-20 coronavirus outbreak ,Pediatrics ,medicine.medical_specialty ,RM ,COVID-19 Vaccines ,Coronavirus disease 2019 (COVID-19) ,Epidemiology ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,[SDV]Life Sciences [q-bio] ,Primary health care ,Primary care ,030204 cardiovascular system & hematology ,Multicentre study ,03 medical and health sciences ,Elderly ,0302 clinical medicine ,SDG 3 - Good Health and Well-being ,RA0421 ,RA0421 Public health. Hygiene. Preventive Medicine ,Virology ,Medicine ,Humans ,030212 general & internal medicine ,Aged ,Vaccine effectiveness ,QR355 ,vaccine effectiveness ,Primary Health Care ,business.industry ,SARS-CoV-2 ,Efetividade da vacina contra COVID-19 ,test-negative design ,Public Health, Environmental and Occupational Health ,COVID-19 ,3rd-DAS ,NIS ,Estados de Saúde e de Doença ,multicentre study ,3. Good health ,RM Therapeutics. Pharmacology ,Vaccination ,Europe ,Determinantes da Saúde e da Doença ,business ,QR355 Virology ,Rapid Communication - Abstract
I-MOVE-COVID-19 primary care study team (in addition to authors above): Nick Andrews, Jamie Lopez Bernal, Heather Whitaker, Caroline Guerrisi, Titouan Launay, Shirley Masse, Sylvie van der Werf, Vincent Enouf, John Cuddihy, Adele McKenna, Michael Joyce, Cillian de Gascun, Joanne Moran, Ana Miqueleiz, Ana Navascués, Camino Trobajo-Sanmartín, Carmen Ezpeleta, Paula López Moreno, Javier Gorricho, Eva Ardanaz, Fernando Baigorria, Aurelio Barricarte, Enrique de la Cruz, Nerea Egüés, Manuel García Cenoz, Marcela Guevara, Conchi Moreno-Iribas, Carmen Sayón, Verónica Gomez, Baltazar Nunes, Rita Roquete, Adriana Silva, Aryse Melo, Inês Costa, Nuno Verdasca, Patrícia Conde, Diogo FP Marques, Anna Molesworth, Leanne Quinn, Miranda Leyton, Selin Campbell, Janine Thoulass, Jim McMenamin, Ana Martínez Mateo, Luca Basile, Daniel Castrillejo, Carmen Quiñones Rubio, Concepción Delgado-Sanz, Jesús Oliva. The I-MOVE-COVID-19 network collates epidemiological and clinical information on patients with coronavirus disease (COVID-19), including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virological characterisation in 11 European countries [1]. One component of I-MOVE-COVID-19 is the multicentre vaccine effectiveness (VE) study at primary care/outpatient level in nine European study sites in eight countries. We measured overall and product-specific COVID-19 VE against symptomatic SARS-CoV-2 infection among those aged 65 years and older. We also measured VE by time since vaccination. This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101003673. info:eu-repo/semantics/publishedVersion
- Published
- 2021
31. Influenza surveillance in Europe: comparing intensity levels calculated using the moving epidemic method
- Author
-
Vega, Tomás, Lozano, José E., Meerhoff, Tamara, Snacken, René, Beauté, Julien, Jorgensen, Pernille, Ortiz de Lejarazu, Raúl, Domegan, Lisa, Mossong, Joël, Nielsen, Jens, Born, Rita, Larrauri, Amparo, and Brown, Caroline
- Published
- 2015
- Full Text
- View/download PDF
32. Concentrations of nitrogen compounds are related to severe rhinovirus infection in infants. A time‐series analysis from the reference area of a pediatric university hospital in Barcelona.
- Author
-
Armero, Georgina, Penela‐Sánchez, Daniel, Belmonte, Jordina, Gómez‐Barroso, Diana, Larrauri, Amparo, Henares, Desiree, Vallejo, Violeta, Jordan, Iolanda, Muñoz‐Almagro, Carmen, Brotons, Pedro, and Launes, Cristian
- Published
- 2022
- Full Text
- View/download PDF
33. Assessing the burden of paediatric influenza in Europe: the European Paediatric Influenza Analysis (EPIA) project
- Author
-
Paget, W. John, Balderston, Catherine, Casas, Inmaculada, Donker, Gé, Edelman, Laurel, Fleming, Douglas, Larrauri, Amparo, Meijer, Adam, Puzelli, Simona, Rizzo, Caterina, Simonsen, Lone, and and all EPIA collaborators
- Published
- 2010
- Full Text
- View/download PDF
34. All‐cause versus cause‐specific excess deaths for estimating influenza‐associated mortality in Denmark, Spain, and the United States.
- Author
-
Schmidt, Sebastian S. S., Iuliano, Angela Danielle, Vestergaard, Lasse S., Mazagatos‐Ateca, Clara, Larrauri, Amparo, Brauner, Jan M., Olsen, Sonja J., Nielsen, Jens, Salomon, Joshua A., and Krause, Tyra G.
- Subjects
INFLUENZA ,PANDEMICS ,MORTALITY ,DEATH rate ,CAUSES of death ,REGRESSION analysis - Abstract
Background: Seasonal influenza‐associated excess mortality estimates can be timely and provide useful information on the severity of an epidemic. This methodology can be leveraged during an emergency response or pandemic. Method: For Denmark, Spain, and the United States, we estimated age‐stratified excess mortality for (i) all‐cause, (ii) respiratory and circulatory, (iii) circulatory, (iv) respiratory, and (v) pneumonia, and influenza causes of death for the 2015/2016 and 2016/2017 influenza seasons. We quantified differences between the countries and seasonal excess mortality estimates and the death categories. We used a time‐series linear regression model accounting for time and seasonal trends using mortality data from 2010 through 2017. Results: The respective periods of weekly excess mortality for all‐cause and cause‐specific deaths were similar in their chronological patterns. Seasonal all‐cause excess mortality rates for the 2015/2016 and 2016/2017 influenza seasons were 4.7 (3.3–6.1) and 14.3 (13.0–15.6) per 100,000 population, for the United States; 20.3 (15.8–25.0) and 24.0 (19.3–28.7) per 100,000 population for Denmark; and 22.9 (18.9–26.9) and 52.9 (49.1–56.8) per 100,000 population for Spain. Seasonal respiratory and circulatory excess mortality estimates were two to three times lower than the all‐cause estimates. Discussion We observed fewer influenza‐associated deaths when we examined cause‐specific death categories compared with all‐cause deaths and observed the same trends in peaks in deaths with all death causes. Because all‐cause deaths are more available, these models can be used to monitor virus activity in near real time. This approach may contribute to the development of timely mortality monitoring systems during public health emergencies. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
35. Assessing the effect of non-pharmaceutical interventions on COVID-19 transmission in Spain, 30 August 2020 to 31 January 2021.
- Author
-
García-García, David, Herranz-Hernández, Rafael, Rojas-Benedicto, Ayelén, León-Gómez, Inmaculada, Larrauri, Amparo, Peñuelas, Marina, Guerrero-Vadillo, María, Ramis, Rebeca, and Gómez-Barroso, Diana
- Published
- 2022
- Full Text
- View/download PDF
36. Excess all-cause mortality during the COVID-19 pandemic in Europe - preliminary pooled estimates from the EuroMOMO network, March to April 2020
- Author
-
Vestergaard, Lasse S, Nielsen, Jens, Richter, Lukas, Schmid, Daniela, Bustos, Natalia, Braeye, Toon, Denissov, Gleb, Veideman, Tatjana, Luomala, Oskari, Möttönen, Teemu, Fouillet, Anne, Caserio-Schönemann, Céline, an der Heiden, Matthias, Uphoff, Helmut, Lytras, Theodore, Gkolfinopoulou, Kassiani, Paldy, Anna, Domegan, Lisa, O'Donnell, Joan, de’ Donato, Francesca, Noccioli, Fiammetta, Hoffmann, Patrick, Velez, Telma, England, Kathleen, van Asten, Liselotte, White, Richard A, Tønnessen, Ragnhild, da Silva, Susana P, Rodrigues, Ana P, Larrauri, Amparo, Delgado-Sanz, Concepción, Farah, Ahmed, Galanis, Ilias, Junker, Christoph, Perisa, Damir, Sinnathamby, Mary, Andrews, Nick, O'Doherty, Mark, Marquess, Diogo FP, Kennedy, Sharon, Olsen, Sonja J, Pebody, Richard, Krause, Tyra G, Mølbak, Kåre, Penttinen, Pasi, Bundle, Nick, Adlhoch, Cornelia, and European Centre for Disease Prevention and Control (ECDC)
- Subjects
Male ,COVID-19 Pandemic ,All-cause Mortality ,Epidemiology ,Covid-19 pandemic ,Disease Outbreaks ,Cause of Death ,Pandemic ,Medicine ,Child ,Excess mortality ,Aged, 80 and over ,Middle Aged ,All-cause mortality ,Europe ,Child, Preschool ,Population Surveillance ,Female ,Coronavirus Infections ,Rapid Communication ,EuroMOMO ,Preliminary Data ,Adult ,medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,Adolescent ,Pneumonia, Viral ,Betacoronavirus ,Young Adult ,Age Distribution ,Virology ,Influenza, Human ,Humans ,Mortality ,Pandemics ,Aged ,Portugal ,business.industry ,SARS-CoV-2 ,Public health ,Public Health, Environmental and Occupational Health ,Infant, Newborn ,COVID-19 ,Infant ,Estados de Saúde e de Doença ,Coronavirus ,business ,Sistema de Vigilância ,All cause mortality ,Demography - Abstract
A remarkable excess mortality has coincided with the COVID-19 pandemic in Europe. We present preliminary pooled estimates of all-cause mortality for 24 European countries/federal states participating in the European monitoring of excess mortality for public health action (EuroMOMO) network, for the period March-April 2020. Excess mortality particularly affected ≥ 65 year olds (91% of all excess deaths), but also 45-64 (8%) and 15-44 year olds (1%). No excess mortality was observed in 0-14 year olds. he EuroMOMO network has received financial support from the European Centre for Disease Prevention and Control (ECDC) and from the World Health Organization (WHO) Regional Office for Europe. We acknowledge all EuroMOMO partners for their contributions as well as the various National Offices of Statistics that are essential partners in ensuring the ongoing monitoring of mortality across Europe. Sí
- Published
- 2020
37. Clinical and epidemiological characteristics of COVID-19 regarding other Severe Acute Respiratory Infections. I-MOVE-COVID19 - Hospital Network / Aragón
- Author
-
Latorre-Millán, Miriam, Mazagatos Clara, Larrauri, Amparo, Rezusta, Antonio, Martínez, Ana María, Martínez, Nieves Felisa, Hernández, María Pilar, Gracia, Yolanda, and Milagro, Ana M
- Published
- 2020
- Full Text
- View/download PDF
38. The first wave of the COVID-19 pandemic in Spain: characterisation of cases and risk factors for severe outcomes, as at 27 April 2020
- Author
-
Redondo-Bravo, Lidia, Sierra Moros, Maria Jose, Martinez Sanchez, Elena Vanessa, Lorusso, Nicola, Carmona Ubago, Alberto, Gallardo Garcia, Virtudes, Sanchez Villanueva, Pilar, Puy Azon, Adela, Guimbao Bescos, Joaquin, Boone, An L. D., Fernandez Ibanez, Ana, Alvarez Fernandez, Blanca, Nicolau Riutort, Antonio, Salom Castell, M. Magdalena, Gimenez Duran, Jaume, Nunez Gallo, Domingo, Rojo Moreno, Magdalena Lucia, Blasco de la Fuente, Aniceto, Viloria Raymundo, Luis Javier, Hernandez Perena, Marcos, Chico Mena, Matilde, Humanes Aparicio, Sonia, Illescas Fernandez, Maria Soledad, Fernandez Arribas, Socorro, Marcos Rodriguez, Ma del Henar, Martinez-Pino, Isabel, Jan, Mireia, Martinez, Ana, Ciruela, Pilar, Villatoro Bongiorno, Katja, March Yague, Aina, Perez Panades, Jordi, Lopez-Tercero Torvisco, Maria del Mar, Gordillo Romero, Cecilia, Caleya Olivas, Beatriz, De Miguel Garcia, Sara, Cordoba Deorador, Esther, Gil Montalban, Elisa, del Valle Arrojo, Manuel, Abraira Garcia, Luisa, Boullosa Cortes, Antonio, Garcia-Fulgueiras, Ana, Dolores Chirlaque, Ma, Isabel Barranco, Ma, Casado, Itziar, Castilla, Jesus, Garcia-Cenoz, Manuel, Gonzalez Carril, Fernando, Soraluce Olaneta, Amaia, Lazaro-Carrasco de la Fuente, Ma Jesus, Martinez Ochoa, Eva, Ibanez Perez, Ana Carmen, Blanco Martinez, Angela, Rivas Perez, Ana Isabel, Ramos Marin, Violeta, Medina Vinuesa, Margarita, Castrillejo Perez, Daniel, Gomez Anes, Atanasio Alfonso, Pozo, Francisco, Casas, Inmaculada, Penalver-Argueso, Belen, Pampaka, Despina, Oliva Dominguez, Jesus A., Sastre Garcia, Maria, Larrauri, Amparo, and Working Grp Surveillance Control C
- Subjects
Male ,sistema de registros ,Epidemiology ,humanos ,adolescente ,pandemias ,Disease ,Comorbidity ,030204 cardiovascular system & hematology ,medicine.disease_cause ,geografía ,0302 clinical medicine ,Risk Factors ,recopilación de datos ,Pandemic ,Medicine ,030212 general & internal medicine ,Registries ,Geography, Medical ,Child ,mediana edad ,Coronavirus ,Aged, 80 and over ,anciano ,Surveillance ,Geography ,Data Collection ,adulto ,Middle Aged ,adulto joven ,Child, Preschool ,Population Surveillance ,Quarantine ,surveillance ,Female ,Algorithms ,Adult ,2019-20 coronavirus outbreak ,medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,Adolescent ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Health Personnel ,Physical Distancing ,algoritmos ,03 medical and health sciences ,Young Adult ,Disease severity ,vigilancia de la población ,Virology ,factores de riesgo ,Humans ,Pandemics ,Aged ,lactante ,business.industry ,SARS-CoV-2 ,pandemic ,Public Health, Environmental and Occupational Health ,COVID-19 ,Infant ,Spain ,Emergency medicine ,Communicable Disease Control ,business - Abstract
Background The first wave of the coronavirus disease (COVID-19) pandemic spread rapidly in Spain, one of Europe’s most affected countries. A national lockdown was implemented on 15 March 2020. Aim To describe reported cases and the impact of national lockdown, and to identify disease severity risk factors. Methods National surveillance data were used to describe PCR-confirmed cases as at 27 April 2020. We compared case characteristics by severity categories (hospitalisation, admission to intensive care unit (ICU), death) and identified severity risk factors using multivariable regression. Results The epidemic peaked on 20 March. Of 218,652 COVID-19 cases, 45.4% were hospitalised, 4.6% were admitted to ICU and 11.9% died. Among those who died, 94.8% had at least one underlying disease. Healthcare workers (HCWs) represented 22.9% of cases. Males were more likely to have severe outcomes than females. Cardiovascular disease was a consistent risk factor. Patients with pneumonia had higher odds of hospitalisation (odds ratio (OR): 26.63; 95% confidence interval (CI): 25.03–28.33). The strongest predictor of death was age ≥ 80 years (OR: 28.4; 95% CI: 19.85–40.78). Among underlying diseases, chronic renal disease had highest odds of death (OR: 1.47; 95% CI: 1.29–1.68). Conclusions COVID-19 case numbers began declining 6 days after the national lockdown. The first wave of the COVID-19 pandemic in Spain had a severe impact on elderly people. Patients with cardiovascular or renal conditions were at higher risk for severe outcomes. A high proportion of cases were HCWs. Enhanced surveillance and control measures in these subgroups are crucial during future COVID-19 waves.
- Published
- 2020
39. 2015/16 to 2017/18 influenza seasons
- Author
-
Machado, Ausenda, Mazagatos, Clara, Dijkstra, Frederika, Kislaya, Irina, Gherasim, Alin, McDonald, Scott A., Kissling, Esther, Valenciano, Marta, Meijer, Adam, Hooiveld, Mariëtte, Nunes, Baltazar, Larrauri, Amparo, Centro de Investigação em Saúde Pública (CISP/PHRC), and Escola Nacional de Saúde Pública (ENSP)
- Subjects
averted cases ,SDG 3 - Good Health and Well-being ,Epidemiology ,Virology ,impact ,Public Health, Environmental and Occupational Health ,influenza vaccine ,influenza - Abstract
BackgroundTo increase the acceptability of influenza vaccine, it is important to quantify the overall benefits of the vaccination programme.AimTo assess the impact of influenza vaccination in Portugal, Spain and the Netherlands, we estimated the number of medically attended influenza-confirmed cases (MAICC) in primary care averted in the seasons 2015/16 to 2017/18 among those ≥ 65 years.MethodsWe used an ecological approach to estimate vaccination impact. We compared the number of observed MAICC (n) to the estimated number that would have occurred without the vaccination programme (N). To estimate N, we used: (i) MAICC estimated from influenza surveillance systems, (ii) vaccine coverage, (iii) pooled (sub)type-specific influenza vaccine effectiveness estimates for seasons 2015/16 to 2017/18, weighted by the proportion of virus circulation in each season and country. We estimated the number of MAICC averted (NAE) and the prevented fraction (PF) by the vaccination programme.ResultsThe annual average of NAE in the population ≥ 65 years was 33, 58 and 204 MAICC per 100,000 in Portugal, Spain and the Netherlands, respectively. On average, influenza vaccination prevented 10.7%, 10.9% and 14.2% of potential influenza MAICC each season in these countries. The lowest PF was in 2016/17 (4.9-6.1%) with an NAE ranging from 24 to 69 per 100,000.ConclusionsOur results suggest that influenza vaccination programmes reduced a substantial number of MAICC. Together with studies on hospitalisations and deaths averted by influenza vaccination programmes, this will contribute to the evaluation of the impact of vaccination strategies and strengthen public health communication. publishersversion published
- Published
- 2019
40. Near real-time surveillance of the SARS-CoV-2 epidemic with incomplete data.
- Author
-
De Salazar, Pablo M., Lu, Fred, Hay, James A, Gómez-Barroso, Diana, Fernández-Navarro, Pablo, Martínez, Elena V, Astray-Mochales, Jenaro, Amillategui, Rocío, García-Fulgueiras, Ana, Chirlaque, Maria D, Sánchez-Migallón, Alonso, Larrauri, Amparo, Sierra, María J, Lipsitch, Marc, Simón, Fernando, Santillana, Mauricio, and Hernán, Miguel A
- Subjects
SARS-CoV-2 ,DISEASE outbreaks ,COMMUNICABLE diseases ,EPIDEMICS ,BASIC reproduction number ,INTEGRATED software ,ACQUISITION of data - Abstract
When responding to infectious disease outbreaks, rapid and accurate estimation of the epidemic trajectory is critical. However, two common data collection problems affect the reliability of the epidemiological data in real time: missing information on the time of first symptoms, and retrospective revision of historical information, including right censoring. Here, we propose an approach to construct epidemic curves in near real time that addresses these two challenges by 1) imputation of dates of symptom onset for reported cases using a dynamically-estimated "backward" reporting delay conditional distribution, and 2) adjustment for right censoring using the NobBS software package to nowcast cases by date of symptom onset. This process allows us to obtain an approximation of the time-varying reproduction number (R
t ) in real time. We apply this approach to characterize the early SARS-CoV-2 outbreak in two Spanish regions between March and April 2020. We evaluate how these real-time estimates compare with more complete epidemiological data that became available later. We explore the impact of the different assumptions on the estimates, and compare our estimates with those obtained from commonly used surveillance approaches. Our framework can help improve accuracy, quantify uncertainty, and evaluate frequently unstated assumptions when recovering the epidemic curves from limited data obtained from public health systems in other locations. Author summary: When surveillance systems cannot be repurposed quickly enough for novel infectious agents, missing information becomes a major challenge in monitoring the outbreak in real time. We propose a statistical approach that uses available data to construct the epidemic curves, which describe the number of individuals infected over time. We apply our 3-step approach to estimate these real-time epidemic curves during the early SARS-CoV-2 outbreak in Spain. We demonstrate that our approach, combined with the understanding of its limitations, can (a) provide useful information earlier and more reliably than conventional surveillance approaches, and (b) aid in the decision-making process towards outbreak mitigation in real-time. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
41. Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain
- Author
-
Larrauri, Amparo, Cano, Rosa, García, Martina, and Mateo, Salvador de
- Published
- 2005
- Full Text
- View/download PDF
42. Using the social ecologic framework to improve the influenza vaccination strategy among the Portuguese elderly
- Author
-
Machado, Ausenda, Santos, Ana João, Kislaya, Irina, Larrauri, Amparo, and Nunes, Baltazar
- Subjects
Influenza Virus ,Vaccination ,Vacina Antigripal ,Determinantes da Saúde e da Doença ,Modelo Sócio Ecológico ,População Idosa - Abstract
Background: In a context of lower than targeted influenza vaccination (IV) coverage, identifying factors associated IV uptake is essential to improve population coverage. Although extensive work has been done in this field, scarcer studies focused on framing these factors within a multifactorial model. Having the social ecological model (SEM) as framework, this study intended to identify and quantify the SEM levels associated to seasonal IV uptake in the Portuguese population aged 65 and more years. Methods: Data from the Portuguese 2014 National Health Survey was restricted to individuals aged 65 and more years (n=5669). The outcome of interest was self-reported IV uptake in the 2 years previous to the interview. Twenty three independent variables were selected from the survey and were allocated in one of the five SEM levels: individual, interpersonal, organizational, community and policy. Sex stratified and age adjusted analysis using Poisson regression were performed for each SEM level. To evaluate statistical significance and marginal contribution of each SEM level for explaining IV uptake, the full model was fitted (all variables from all 5 SEM levels). To determine joint statistical significance of variables of each SEM level, the model without respective SEM level was compared with the full model using likelihood ratio test. Additionally, marginal contribution of each SEM level was measured by relative reduction in magnitude of pseudo R square. Results: For both men and women, older age groups (85 or more vs 65-69 age group; PR=1.59 for men and PR=1.56 for women); having 3 or more chronic conditions (PR=1.39 for men and PR=1.35 for women); number of GP and outpatient visits in the previous 4 weeks were associated to higher IV uptake. For men, only 2 out of the 5 SEM levels were associated to IV uptake (individual and organizational). For women 3 levels were relevant for this preventive measure (individual, organizational and community). Main marginal contribution for explaining the IV uptake, came from individual (17.9% and 16.3%) and organizational (30.7% and 22.7%) levels for both men and women respectively. Conclusions: Besides individual characteristics, like age and health status - known determinants of IV uptake - this study highlights the importance of access and use of health care services for adoption of IV preventive measure. Moreover, it evidences a sex differential behaviour that should be accounted in the definition of the IV campaign strategy. N/A
- Published
- 2019
43. S-adenosyl-L-methionine reverses the cholestatic effect of ethinylestradiol in rat hepatocytes by increasing its catabolism
- Author
-
Larrauri, Amparo, Castell, José V., Garrido, Guillermo, Berenguer, Joaquín, and Gómez-lechón, M. José
- Published
- 1992
- Full Text
- View/download PDF
44. Preparing for an influenza season 2021/22 with a likely co-circulation of influenza virus and SARS-CoV-2.
- Author
-
Larrauri, Amparo and Trilar, Katarina Prosenc
- Published
- 2021
- Full Text
- View/download PDF
45. No effect modification of influenza virus vaccine effectiveness by age or chronic condition was observed in the 2010/11 to 2017/18 seasons.
- Author
-
Machado, Ausenda, Leite, Andreia, Larrauri, Amparo, Gomez, Verónica, Rodrigues, Ana Paula, Kislaya, Irina, and Nunes, Baltazar
- Abstract
Purpose Most European influenza vaccine strategies target individuals at higher risk of complications, which include, among others, individuals aged ≥65 years and with chronic conditions. These individuals not only have a high‐risk of post‐infection complications but also could have lower capacity of acquiring adequate vaccine‐induced protection. As such, chronic conditions and age could modify the effect of vaccines. This study aimed at assessing the potential effect modification of influenza vaccine effectiveness (IVE) by age and chronic conditions. Methods: We used eight‐season data from the Portuguese vaccine effectiveness study. Every season, physicians at primary care units recruited patients with influenza‐like illness. Clinical data and swabs were collected for Reverse Transverse Polymerase Chain Reaction (RT‐PCR) detection of influenza. Trivalent inactivated IVE was estimated as 1 – odds ratio (OR) of being vaccinated in cases (RT‐PCR positive for influenza) versus negative controls. ORs were obtained using a multivariable conditional logistic regression model, paired by week of onset within each season. Confounders were assessed by designing a specific causal diagram. Age (< 65 or ≥65 years) and chronic conditions (diabetes, cardiovascular disease, chronic renal disease, chronic hepatic disease, obesity, chronic respiratory disease, and congenital or acquired immunodeficiency) were studied as effect modifiers by including an interaction term in the regression models. Significance was established at 5%. Results: Point estimates indicate a higher IVE in the chronic condition strata compared to that in the no chronic condition strata. Regarding age, different results were obtained considering the virus type and (sub)type. When comparing the ≥65 years with the <65 years of age strata, we observed a higher IVE against A(H1N1)pdm09, an equal IVE against A(H3N2) and a lower IVE against B virus. However, all interaction terms were statistically insignificant, and this may be due to a small sample size. Conclusion: The potential effect modification of age or chronic condition was not observed within our study. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
46. Culture of human hepatocytes from small surgical liver biopsies. Biochemical characterization and comparison with in vivo
- Author
-
Gómez-Lechón, M. José, López, Pilar, Donato, Teresa, Montoya, Angel, Larrauri, Amparo, Giménez, Patricia, Trullenque, Ramón, Fabra, Ricardo, and Castell, José V.
- Published
- 1990
- Full Text
- View/download PDF
47. Influenza coverages in Spain and vaccination-related factors in the subgroup aged 50–64 years
- Author
-
Jiménez, Rodrigo, Larrauri, Amparo, Carrasco, Pilar, Esteban, Jesús, Gómez-López, Luis Ignacio, and Gil, Ángel
- Published
- 2003
- Full Text
- View/download PDF
48. Effectiveness of mRNA COVID-19 vaccines in preventing SARS-CoV-2 infections and COVID-19 hospitalisations and deaths in elderly long-term care facility residents, Spain, weeks 53 2020 to 13 2021.
- Author
-
Mazagatos, Clara, Monge, Susana, Olmedo, Carmen, Vega, Lorena, Gallego, Pilar, Martín-Merino, Elisa, Sierra, María José, Limia, Aurora, and Larrauri, Amparo
- Published
- 2021
- Full Text
- View/download PDF
49. Influenza-attributable mortality in the Iberian Peninsula, seasons 2012/13 - 2017/18
- Author
-
Mazagatos, Clara, Silva, Susana Pereira, Delgado-Sanz, Concha, Rodrigues, Ana Paula, Oliva, Jesus, Nunes, Baltazar, and Larrauri, Amparo
- Subjects
Gripe ,Mortalidade ,Estados de Saúde e de Doença - Abstract
Introduction / Objectives: Influenza has a considerable impact on mortality. Significant excess all-cause mortality is often observed during winter seasons, mainly among the elderly. Quantifying the mortality associated to influenza is important to estimate the real impact of seasonal influenza epidemics on the population. Our objective is to estimate the influenza-attributable mortality in Portugal and Spain for seasons 2012-13 to 2017-18 Methodology: To estimate influenza-attributable mortality in both countries, a multiplicative Poisson regression time-series model (FluMOMO) with over-dispersion corrected for trend and seasonality, with ISO-week as time unit was used. We estimated influenza-attributable deaths and mortality rates (and their 95% CIs), for all ages and by age group (
- Published
- 2018
50. Exploring the effect of previous inactivated influenza vaccination on seasonal influenza vaccine effectiveness against medically-attended influenza: results of the European I-MOVE multicentre test-negative case-control study, 2011/12-2016/17
- Author
-
Valenciano, Marta, Kissling, E, Larrauri, Amparo, Nunes, Baltasar, Pitigoi, Daniela, O Donnell, Joan, Reuss, Annicka, Horváth, Judit Krisztina, Paradowska-Stankiewicz, Iwona, Rizzo, Caterina, Falchi, Alessandra, Daviaud, Isabel, Brytting, Mia, Meijer, Adam, Kaic, Bernard, Gherasim, Alin, Machado, Ausenda, Ivanciuc, Alina, Domegan, Lisa, Schweiger, Brunhilde, Ferenczi, Annamária, Korczyńska, Monika, Bella, Antonino, Vilcu, Ana-Maria, Mosnier, Anne, Zakikhany, Katherina, Filipovićović, Sanja Kurečić, Johansen, Kari, Moren, Alain, and de Lange, Marit
- Subjects
virus diseases - Abstract
Results of previous influenza vaccination effects on current season influenza vaccine effectiveness (VE) are inconsistent.
- Published
- 2018
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.